TrialNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2018

Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.

Jordi Bruna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.